TNFα Blockade Therapy has been associated with invasive fungal infections, including histoplasmosis, candidiasis, and aspergillosis, with a review from 2008 identifying 64 reported cases of IPA in patients receiving TNFα blockers, with an overall mortality rate of 82% [95]. This evidence concerns the gene TNF and candidiasis.